Managing chikungunya arthritis using etanercept
DOI:
https://doi.org/10.15305/ijrci/v7i1/307Abstract
Chikungunya virus or Aedes-borne alpha virus causes infection through an acute viremic phase and a chronic arthritis phase. The present study highlights the benefits of using etanercept for managing chikungunya arthritis, especially in scenarios where NSAIDS and steroids are contraindicated due to multiple comorbidities.
References
Sam I-C, Kümmerer BM, Chan Y-F, Roques P, Drosten C, AbuBakar S. Updates on chikungunya epidemiology, clinical disease, and diagnostics. Vector Borne Zoonotic Dis. 2015 Apr;15(4):223–30.
Sutaria RB, Amaral JK, Schoen RT. Emergence and treatment of chikungunya arthritis. Curr Opin Rheumatol. 2018;30(3):256–63.
Arthritis-India [Internet]. [cited 2019 May 1]. Available from: http://www.arthritis-india.com/chikungunya-arthritis.html
Dash PK, Parida MM, Santhosh SR, Verma SK, Tripathi NK, Ambuj S, et al. East Central South African genotype as the causative agent in reemergence of Chikungunya outbreak in India. Vector Borne Zoonotic Dis. 2007;7(4):519–27
Chikungunya [Internet]. [cited 2019 May 1]. Available from: https://www.who.int/news-room/fact-sheets/detail/chikungunya
Krutikov M, Manson J. Chikungunya Virus Infection: An Update on Joint Manifestations and Management. Rambam Maimonides Med J. Rambam Maimonides Med J. 2016 Oct; 7(4): e0033.
Blettery M, Brunier L, Polomat K, Moinet F, Deligny C, Arfi S, et al. Brief Report: Management of Chronic Post-Chikungunya Rheumatic Disease: The Martinican Experience. Arthritis & Rheumatology (Hoboken, NJ). 2016;68(11):2817–24.
Zaid A, Gérardin P, Taylor A, Mostafavi H, Malvy D, Mahalingam S. Chikungunya Arthritis: Implications of Acute and Chronic Inflammation Mechanisms on Disease Management. Arthritis & Rheumatology (Hoboken, NJ). 2018 Apr;70(4):484–95.
Zaid A, Rulli NE, Rolph MS, Suhrbier A, Mahalingam S. Disease exacerbation by etanercept in a mouse model of alphaviral arthritis and myositis. Arthritis Rheum. 2011 Feb;63(2):488–91.
Published
Issue
Section
License
Copyright for articles published in this journal is retained by the authors, with first publication rights granted to the ‘Internet Journal of Rheumatology and Clinical Immunology’. All the published content, except where otherwise noted, is licensed under Creative Commons license (CC-BY).
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) after the publication of the manuscript in IJRCI, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
